[A20-33] Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94

Last updated 14.05.2020

Project no.:
A20-33

Commission:
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Indication:

Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy

Result of dossier assessment:

Due to new information from the commenting procedure now hint of a non-quantifiable added benefit.

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Project no. Title Status
A19-94 Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V Commission completed

Federal Joint Committee (G-BA)

2020-05-14 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.